These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 7994783)

  • 1. A randomized trial of early intravesical instillation of epirubicin in superficial bladder cancer. The Nagoya University Urological Oncology Group.
    Okamura K; Murase T; Obata K; Ohshima S; Ono Y; Sakata T; Hasegawa Y; Shimoji T; Miyake K
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S31-5. PubMed ID: 7994783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer. Tokyo Women's Medical College Bladder Cancer Collaborating Group.
    Ryoji O; Toma H; Nakazawa H; Goya N; Okumura T; Sonoda T; Kihara T; Tanabe K; Onizuka S; Tomoe H
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S60-4. PubMed ID: 7994789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of intravesical chemoprophylaxis of epirubicin after transurethral resection of bladder tumors. Tottori University Oncology Group.
    Watanabe N; Miyagawa I; Higasibori Y; Nakahara T; Sumi F; Ishida G; Abe B; Inoue A; Hanamoto N
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S57-9. PubMed ID: 7994788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group.
    Eto H; Oka Y; Ueno K; Nakamura I; Yoshimura K; Arakawa S; Kamidono S; Obe S; Ogawa T; Hamami G
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S46-51. PubMed ID: 7994786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report.
    Uekado Y; Hirano A; Shinka T; Ohkawa T
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S65-8. PubMed ID: 7994790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intravesical instillation of epirubicin in the prophylactic treatment of recurrent superficial bladder cancer].
    Kobayashi M; Sugaya Y; Yuzawa M; Morita T; Kobayashi Y; Tokue A
    Hinyokika Kiyo; 1998 Dec; 44(12):861-4. PubMed ID: 10028430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study.
    Saika T; Tsushima T; Nasu Y; Miyaji Y; Saegusa M; Takeda K; Kumon H
    World J Urol; 2010 Aug; 28(4):413-8. PubMed ID: 20054553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of prophylactic intravesical chemotherapy with 4'-epirubicin in recurrent superficial bladder cancer: comparison of 4'-epirubicin and adriamycin.
    Shuin T; Kubota Y; Noguchi S; Hosaka M; Miura T; Kondo I; Fukushima S; Ishizuka E; Furuhata A; Moriyama M
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S52-6. PubMed ID: 7994787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer.
    Tozawa K; Okamura T; Sasaki S; Kawai N; Ito Y; Hayashi Y; Kohri K
    Urol Int; 2001; 67(4):289-92. PubMed ID: 11741130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
    Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
    Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
    Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
    Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
    J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group.
    Okamura K; Kinukawa T; Tsumura Y; Otani T; Itoh H; Kobayashi H; Matsuura O; Kobayashi M; Fukatsu T; Ohshima S
    Eur Urol; 1998; 33(3):285-8; discussion 289. PubMed ID: 9555553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha 2-b interferon and farmarubicin in the prophylaxis of recurrence of superficial transitional cell carcinoma of the urinary bladder.
    Cervenakov I; Szoldova K; Mardiak J; Chovan D; Mala M; Slavov D
    Bratisl Lek Listy; 2000; 101(6):317-20. PubMed ID: 11039202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
    Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
    J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder.
    Oosterlinck W; Kurth KH; Schröder F; Bultinck J; Hammond B; Sylvester R
    J Urol; 1993 Apr; 149(4):749-52. PubMed ID: 8455236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
    Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH
    Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of the preoperative intravesical instillation of doxorubicin and the oral administration of 5-fluorouracil in preventing recurrence after a transurethral resection of superficial bladder cancer. Kyushu University Urological Oncology Group.
    Naito S; Iguchi A; Sagiyama K; Ariyoshi A; Osada Y; Omoto T; Kuriya N; Kumazawa J
    Int J Urol; 1997 Jul; 4(4):352-7. PubMed ID: 9256323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.
    Mitsumori K; Tsuchiya N; Habuchi T; Li Z; Akao T; Ohyama C; Sato K; Kato T
    BJU Int; 2004 Aug; 94(3):317-21. PubMed ID: 15291859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy with early intravesical instillation of adriamycin and long-term oral administration of 5-fluorouracil in superficial bladder cancer. The Kyushu University Urological Oncology Group.
    Ueda T; Naito S; Iguchi A; Sagiyama K; Osada Y; Ariyoshi A; Omoto T; Kumazawa J
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S31-6. PubMed ID: 1394813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.